The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:
Kari Jussi Aho
Matti Kavetvuo was elected Chairman of the Committee.
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board. The term of the Nomination Committee shall end at the closing of the next Annual General Meeting of the company.
The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at http://www.orion.fi/board_committees, a page in the Corporate Governance section of the Orion Group internet website.
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Timo Lappalainen, President and CEO, phone +358 10 426 3692
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.